Drug Profile
Octreotide controlled-release - Peptron
Alternative Names: PT 201; SR Octreotide - PeptronLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Peptron
- Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acromegaly
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Acromegaly in Canada (SC, Controlled release)
- 11 Feb 2014 Phase-I clinical trials in Acromegaly in Canada prior to 2014 (SC, controlled-release)